首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > 處方藥 > 癌治療的新動向:低分子藥•生物製劑
產業/市場分類
製藥 (4495)
肥胖症治療 (48)
非專利藥 (117)
疫苗 (168)
神經疾病 (175)
骨頭疾病治療 (41)
動物用醫藥 (18)
處方藥 (89)
規章 (107)
感染疾病 (318)
精神病 (80)
製藥企業 (506)
糖尿病 (157)
癌症 (838)
藥物開發 (1275)
DDS (173)
OTC 非處方藥 (147)
市場調查報告書

癌治療的新動向:低分子藥•生物製劑

Emerging Trends in Cancer Therapies (Small Molecule Drugs and Biologicals)

出版商 Technical Insights, Inc.
出版日期 2008年06月 商品編碼 70270
內容資訊 英文  
價格
US $ 6500 Web Access (Regional License)
US $ 7000 Hard Copy & Web Access (Regional License)


癌治療的新動向:低分子藥•生物製劑 是由出版商Technical Insights, Inc.在2008年06月所出版的。 這份英文市場調查報告書價格從美金6500起跳。

簡介

此報告書調查分析了癌治療的低分子藥•生物製劑相關新動向,並且還依照企業、學術機關彙整了開發事例、技術動向、技術導入牽動因素、導入中的障礙、專利•企業資料等內容。報告書之內容摘要如下所示。

第1章 摘要

  • 調查範圍•調查手法
  • 產業概要
    • 抗癌治療產業概要
    • 主要調查結果

第2章 技術動向•導入牽動因素

  • 癌治療的技術動向
    • 抗癌治療方法的新動向:診斷•治療•藥物輸送
    • 癌研究的潛在性市場機會分析
  • 戰略分析•建議
    • 抗癌劑治療的成長牽動因素
    • 抗癌治療的成長阻礙因素
    • 戰略性建議
    • 未來將會影響癌治療的技術
    • 癌研究的財源
    • 企業M&A

第3章 全球癌治療開發動向

  • 企業
    • 用於GIST•RCC治療的經口激酶阻礙劑
    • 用於轉移性乳癌治療的VEGF阻礙劑
    • 用於肝細胞癌的雙重作用肝黏醣硫酸鹽
    • 在癌診斷•治療中持有多重用途的獨自技術
    • 用於末梢T細胞性淋巴瘤的次世代低分子藥
    • 用於轉移性黑色瘤治療的殺癌病毒技術
    • 用於癌診斷的自動FISH技術
    • 對於癌•免疫疾病自體抗原之克服免疫耐受性的新技術
    • 用於發現新癌治療層級的技術平台
    • 用於癌治療的劃時代微脂體藥物輸送技術、等
  • 學術機關
    • 端粒酶相關蛋白質的發現與抗腫瘤治療
    • 根據Nanoworm的腫瘤標的•癌影像診斷

第4章 智慧財產方案•主要企業&大學等

第5章 決策支援資料庫

目錄

Abstract

This research service analyzes the emerging trends in cancer therapies with respect to small molecule drugs and biologicals.

Table of Contents

1. EXECUTIVE SUMMARY

Scope and Methodology

  • Scope and Segmentation
  • Methodology

Industry Overview

  • An Overview of AntiCancer Therapeutics Industry
  • Key Findings

2. TECHNOLOGY TREND AND ADOPTION FACTOR ANALYSIS

Technology Trends in Cancer Therapies

  • Emerging Trends in Anticancer Therapeutic Approaches-- Diagnostics; Therapeutics; and Drug Delivery
  • Analysis of Potential Opportunities for Cancer Research

Strategic Analysis and Recommendations

  • Growth Accelerating Factors for Anticancer Drug Therapies
  • Growth Restraining Factors for Anticancer Therapies
  • Strategic Recommendations
  • Technologies Impacting Future of Cancer Therapy
  • Cancer Research Funding Sources
  • Corporate Mergers and Acquisitions

3. GLOBAL DEVELOPMENTS IN CANCER THERAPIES

Noteworthy Developments in Corporate Sector

  • Kinase Inhibiing Oral Drug to Treat GIST and Renal Cell Carcinoma
  • VEGF Inhibitor Drug Effectively Treats Metastatic Breast Cancer
  • Dual Action Heparan Sulphate Mimetic for Hepatocellular Carcinoma
  • Unique Technology with Multiple Applications for Cancer Diagnosis and Therapy
  • Next Generation Small Molecule Drug for Peripheral T-cell Lymphomas
  • Cancer Killing Virus Technology to Treat Metastatic Melanoma
  • Automated FISH Technology for Cancer Diagnosis
  • Novel Technology that Overcomes Immune Tolerance to Self Antigens in Cancer and Immunological Diseases
  • Novel Technology Platform for Discovery of Novel Class of Cancer Therapeutics
  • Ground Breaking Liposomal Drug Delivery Technology for Cancer Therapy
  • Disease Specific Microarray for the Development of Diagnostic and prognostic Tests for Cancer
  • Novel Therapy to Treat Malignant Glioma
  • DNA Interference Drug to Treat Cancer and Genetic Diseases
  • Personalized Cancer Diagnostic Test Aids the Selection of Chemotherapeutic Drugs

Noteworthy Developments in Academia

  • Discovery of Telomerase Related Proteins Raises Hopes of Antitumor Therapy
  • Nanoworms Enable Tumor Targeting and Diagnostic Imaging of Cancers

4. INTELLECTUAL PROPERTY SCENARIO AND KEY INDUSTRY PARTICIPANTS

Patent Details

  • Corporate Sector
  • Academic Sector

Contact Details

  • Industry Participants
  • University and Academia

5. DECISION SUPPORT DATABASE

Decision Support Tables

  • Number of Biotech Companies (2002 to 2012)
  • Venture Capital Investment in Biotechnology (2002 to 2012)
  • Incidence of Breast Cancer (2002 to 2012)
  • Incidence of Prostate Cancer (2002 to 2012)
  • Incidence of Bladder Cancer (2002 to 2012)
  • Incidence of Liver Cancer (2002 to 2012)
Back to Top